CIMETIDINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Cimetidine Hydrochloride patents expire, and when can generic versions of Cimetidine Hydrochloride launch?
Cimetidine Hydrochloride is a drug marketed by Cosette, Endo Operations, Hospira, Luitpold, Teva Parenteral, Ani Pharms, Chartwell Molecular, Cycle, G And W Labs Inc, Pai Holdings Pharm, Pharm Assoc, and Pharmobedient Cnsltg. and is included in twenty-one NDAs.
The generic ingredient in CIMETIDINE HYDROCHLORIDE is cimetidine hydrochloride. There are twenty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cimetidine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cimetidine Hydrochloride
A generic version of CIMETIDINE HYDROCHLORIDE was approved as cimetidine hydrochloride by PAI HOLDINGS PHARM on October 28th, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CIMETIDINE HYDROCHLORIDE?
- What are the global sales for CIMETIDINE HYDROCHLORIDE?
- What is Average Wholesale Price for CIMETIDINE HYDROCHLORIDE?
Summary for CIMETIDINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 12 |
NDAs: | 21 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 57 |
Clinical Trials: | 65 |
Patent Applications: | 794 |
DailyMed Link: | CIMETIDINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for CIMETIDINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 4 |
University of Washington | Phase 4 |
Wollo University | Phase 4 |
Pharmacology for CIMETIDINE HYDROCHLORIDE
Drug Class | Histamine-2 Receptor Antagonist |
Mechanism of Action | Histamine H2 Receptor Antagonists |